DBV Technologies (DBVT) Receivables - Other (2015 - 2026)
DBV Technologies (DBVT) posted Receivables - Other of $2.6 million for Q2 2026, up 160.0% sequentially from $1.0 million in Q1 2026, and down 9.88% YoY from $2.9 million in Q2 2025.
DBV Technologies (DBVT) Receivables - Other (2015 - 2026) Analysis & Trends
DBV Technologies has reported Receivables - Other for 12 years, with the latest figure at $2.6 million in Q2 2026.
- Quarterly Receivables - Other fell 9.88% year-over-year to $2.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.6 million (down 9.88% YoY) and the FY2025 annual result came in at $1.6 million, down 18.33% from the prior year.
- Receivables - Other rose to $2.6 million in Q2 2026 per DBVT's latest filing, from $1.0 million in the prior quarter.
- Over five years, Receivables - Other peaked at $4.8 million in Q3 2024 and troughed at $518000.0 in Q1 2024.
- A 5-year average of $1.9 million and a median of $1.5 million in 2022 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2023 and 2024: Receivables - Other jumped 241.49% in 2023, then tumbled 81.43% in 2024.
- Over 5 years, Receivables - Other stood at $1.5 million in 2022, then dropped by 10.04% to $1.4 million in 2023, then surged by 44.79% to $2.0 million in 2024, then fell by 18.33% to $1.6 million in 2025, then jumped by 62.5% to $2.6 million in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $2.6 million, $1.0 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Jun 30, 2026 | 2.60 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | 4.84 Mn |
| Sep 30, 2024 | 4.84 Mn |
| Jun 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 3.42 Mn |
| Mar 31, 2024 | 518,000.00 |
| Mar 31, 2024 | 518,000.00 |